Donate to the Melanoma Network of Canada

Welcome to the Melanoma Network of Canada.

We need to make a change in the direction of this disease.The incidence rates of melanoma and other skin cancers make this the number one most frequently diagnosed cancer worldwide. In Canada, melanoma is the 7th most commonly diagnosed cancer, affecting over 6,800 people and is one of the most common cancers in our youth ages 15 to 29.

But there is hope! Our donors and volunteers make a huge impact in the lives of those affected by melanoma and skin cancer, funding vital research, patient support programs and awareness education.

We are here for you. Patients, health-care professionals, anyone who wants to learn more and create a future without melanoma!

Contact Us. Volunteer. Donate.

Walks Across Canada
Kms Walked

Thank you for your support

I don’t know what I would have done or where I’d be without MNC. I found people that understood what I was going through, how I was feeling and what steps I needed to take to get my questions answered so I could sleep at night again. Not only have I found a place with MNC but my husband and grown ‘kids’ have too, as well as friends, family and extended family.

Sue Cox, Vancouver Walk Coordinator & Melanoma Survivor

My younger brother, Liam, was diagnosed with melanoma in October 2011 at the age of 36. I immediately started sourcing information on melanoma and supports available for him and our family. I was so grateful to find MNC. I was able to find a source of information, right here in Canada, which I will be forever grateful for finding. From the discussion forums on the website to emails from Annette, I found the support we needed.

Seana Blanchard, Dartmouth Walk Coordinator

Cobimetinib Survey

Melanoma Network of Canada is providing a submission to relay patient’s experiences with these drugs as well as perspectives from other patients and caregivers on the unmet needs for treatment. We are looking for all patients input, but particularly want to hear from those who have also been treated with Cobimetinib (GDC-093/XL518). Your input on this 20 minute survey may be invaluable!